Clinical Trials Logo

Clinical Trial Summary

The purpose of this research is to compare the diagnostic yields of the WATS approach versus the updated Sydney protocol (five standard biopsies in the three gastric regions). ā€¢ We hypothesize that the WATS technology will increase the overall diagnostic yield up to 35% of gastric premalignant lesions and early gastric cancer. To explore the performance of the existing and novel biomarkers, including the IHCs p53 and MUC2. - We anticipate concordance of the existing biomarkers as adjuncts to the diagnosis. - To accomplish this aim, we will analyze current biomarkers on all study subjects (Aim 1), as well as explore novel gastric biomarkers.

Clinical Trial Description

We expect that this study will advance the field of gastric cancer early detection, surveillance and prevention. - We hypothesize that a streamlined clinical protocol and SOP will emerge. - We anticipate that this approach will enhance clinical practice as it has in Barrett's esophagus. This comes at a time when endoscopy imaging capabilities are advancing to eventually permit targeted sampling by WATS. - We expect novel biomarkers to be incorporated into WATS clinical practice for gastric neoplasia, based upon discovery (Aim 2). - We will advance the implementation science as we elucidate the barriers to gastric cancer screening in the diverse populations in this study (Scarinci). - We fully expect this study to alter clinical practice and to develop into a variety of ongoing funding pathways. We hypothesize that the WATS will increase the overall histology diagnostic yield by up to 35% and the specific diagnostic yield of gastric intestinal metaplasia (from 20% to 30%), and dysplasia (from 2% to 10%) and early gastric cancer (from 1% to 3%). The examination of novel WATS biomarkers (IHCs) such as gH2AX and the mucins (Aim 2) is exploratory. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05028296
Study type Interventional
Source University of Alabama at Birmingham
Contact Douglas Morgan, MD
Phone 205-975-9564
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date January 1, 2022
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03746704 - Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Participants With Advanced PD-L1 Positive Malignancies Phase 1
Not yet recruiting NCT04105062 - LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery Phase 1/Phase 2
Not yet recruiting NCT05052931 - Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer Phase 2
Recruiting NCT04082364 - Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Active, not recruiting NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Not yet recruiting NCT04535414 - Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers Phase 2
Recruiting NCT04249739 - Pembrolizumab + Capecitabineļ¼¸Oxaliplatin (CapeOx) Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04062656 - Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG Phase 2
Recruiting NCT04354662 - Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer Phase 2
Recruiting NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Not yet recruiting NCT03273920 - Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer N/A
Active, not recruiting NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04553692 - Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A